DDInter1939 DDInter1376
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting. A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Vinorelbine {u} (Compound) resembles {v} (Compound) Vincristine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinblastine
Vinorelbine {u} (Compound) treats {v} (Disease) hematologic cancer
Vinorelbine {u} (Compound) binds {v} (Gene) TUBB4B
Vinorelbine {u} (Compound) upregulates {v} (Gene) LAMC2
Vinorelbine {u} (Compound) is included by {v} (Pharmacologic Class) Vinca Alkaloids
Vinorelbine {u} (Compound) downregulates {v} (Gene) IARS2
Vinorelbine {u} (Compound) causes {v} (Side Effect) Angina pectoris
Vinorelbine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Vinorelbine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Vinorelbine (Compound) resembles Vincristine (Compound)
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
Vinorelbine (Compound) treats hematologic cancer (Disease)
Vinorelbine (Compound) binds TUBB4B (Gene)
Vinorelbine (Compound) upregulates LAMC2 (Gene)
Vinorelbine (Compound) is included by Vinca Alkaloids (Pharmacologic Class)
Vinorelbine (Compound) downregulates IARS2 (Gene)
Vinorelbine (Compound) causes Angina pectoris (Side Effect)
Vinorelbine may cause a minor interaction that can limit clinical effects when taken with Modafinil
Vinorelbine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin